Cytori Therapeutics Inc Stock Nasdaq
Stocks
US23283K4022
Biotechnology & Medical Research
| Market Cap | 21.4M 18.46M 17.37M 15.82M 29.75M 2.03B 29.91M 205M 79.91M 1.03B 80.36M 78.61M 3.43B | P/E 2026 * |
-0.56x | P/E 2027 * | -1.18x |
|---|---|---|---|---|---|
| Enterprise Value | 21.4M 18.46M 17.37M 15.82M 29.75M 2.03B 29.91M 205M 79.91M 1.03B 80.36M 78.61M 3.43B | EV / Sales 2026 * |
2.27x | EV / Sales 2027 * | 1.12x |
| Free-Float |
98.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Cytori Therapeutics Inc
| 1 day | +10.18% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 2014-04-01 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 2020-02-05 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 2025-10-20 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 2002-09-30 |
Richard Hawkins
CHM | Chairman | 77 | 2018-01-24 |
| Director/Board Member | 66 | 2019-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.18% | -19.62% | - | - | 21.4M | |
| +0.21% | -2.69% | +1.19% | +17.32% | 49.81B | |
| +1.52% | -1.40% | +427.26% | +494.65% | 44.06B | |
| -0.61% | -0.09% | +41.06% | +15.53% | 42.99B | |
| -0.62% | -5.05% | +7.63% | +71.06% | 40.88B | |
| -0.48% | -3.09% | +17.78% | +49.80% | 33.11B | |
| -1.45% | -4.58% | +23.79% | +114.24% | 16.58B | |
| -1.41% | +2.35% | - | - | 17.27B | |
| -1.35% | -3.40% | +10.13% | +26.34% | 14.63B | |
| -1.93% | -5.03% | +75.29% | +34.84% | 13.76B | |
| Average | +0.42% | -1.64% | +75.51% | +102.97% | 30.34B | |
| Weighted average by Cap. | -0.26% | -1.79% | +90.41% | +119.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.44M 8.14M 7.66M 6.98M 13.12M 896M 13.19M 90.54M 35.24M 456M 35.44M 34.67M 1.51B | 19.14M 16.51M 15.53M 14.15M 26.61M 1.82B 26.75M 184M 71.46M 924M 71.86M 70.31M 3.06B |
| Net income | -34.22M -29.51M -27.76M -25.29M -47.56M -3.25B -47.82M -328M -128M -1.65B -128M -126M -5.48B | -18.45M -15.92M -14.97M -13.64M -25.65M -1.75B -25.79M -177M -68.9M -891M -69.29M -67.79M -2.95B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
